ey0015.1-5 | New mechanisms | ESPEYB15
L Cheung , P Le Tissier , SG Goldsmith , M Treier , R Lovell-Badge , K Rizzoti
ey0015.9-2 | Late consequences of tumour therapy: prevention and monitoring | ESPEYB15
L Collins , L Beaumont , A Cranston , S Savoie , T Nayiager , R Barr
ey0015.9-13 | Biologic agents in chronic inflammatory diseases: lights and shadows | ESPEYB15
L Haas , R Chevalier , BT Major , F Enders , S Kumar , J Tung
ey0015.11-2 | New insight into obesity comorbidities | ESPEYB15
G Zabarsky , C Beek , E Hagman , B Pierpoint , S Caprio , R Weiss
ey0015.13-7 | How does paediatric endocrinology and diabetes fit in the global initiatives? | ESPEYB15
S Horton , R Sullivan , J Flanigan , KA Fleming , MA Kuti , LM Looi , SA Pai , M Lawler
ey0015.13-10 | Type 1 and Type 2 Diabetes in Resource-Limited Settings | ESPEYB15
R Atun , JI Davies , EAM Gale , T Barnighausen , D Beran , AP Kengne
ey0015.13-13 | Type 1 and Type 2 Diabetes in Resource-Limited Settings | ESPEYB15
ME Robinson , K Altenor , C Carpenter , R Bonnell , E Jean-Baptiste , J von Oettingen
ey0015.13-14 | Type 1 and Type 2 Diabetes in Resource-Limited Settings | ESPEYB15
E Wheeler , A Leong , CT Liu , MF Hievert , R Strawbridge , C Podmore
ey0015.14-2 | And why do women live longer? | ESPEYB15
V Zarulli , JA Barthold Jones , A Oksuzyan , R Lindahl-Jacobsen , K Christensen , JW Vaupel
ey0015.14-12 | The ‘nocebo’ effect: psychogenic but truly harmful | ESPEYB15
A Gupta , D Thompson , A Whitehouse , T Collier , B Dahlof , N Poulter , R Collins , P Sever , Investigators ASCOT